
hug.ch
Apr 14, 2025, 03:45
Alfredo Addeo: The Phase 3 DeLLphi-304 trial met its primary endpoint
Alfredo Addeo, Head of Oncology Department at Geneva University Hospitals, shared a post on X:
“Breaking: The Phase 3 DeLLphi-304 trial met its primary endpoint: Imdelltra (tarlatamab-dlle) significantly improved overall survival vs SOC in SCLC patients post-platinum. A major step forward for this hard-to-treat disease. Look forward to seeing the data.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 17, 2025, 16:34
Apr 17, 2025, 16:21
Apr 17, 2025, 16:13